Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity

1 Jul 2006

Abstract excerpt

PURPOSE: The use of the CD20-specific antibody rituximab has greatly improved the response to treatment of CD20+ follicular lymphoma. Despite the success of rituximab, resistance has been reported and prognostic markers to predict individual response are lacking. The level of CD20 expression on tumors has been related to response, but results of several studies are contradictory and no clear relationship could be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16818702
DOI: 10.1158/1078-0432.ccr-06-0066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicityPMID 16818702Read ↗

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector MechanismsSemantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burdenSemantic proximity Read ↗

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.Semantic proximity Read ↗

High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.Semantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.Semantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodiesSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesSemantic proximity Read ↗

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.